Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 12:2021:7932721.
doi: 10.1155/2021/7932721. eCollection 2021.

Study on the Effect of Combination of Prednisone and Vitamin D in the Treatment of Primary Nephrotic Syndrome in Children

Guoqun Zhou  1 , Xiangdong Kong  2
Affiliations

Study on the Effect of Combination of Prednisone and Vitamin D in the Treatment of Primary Nephrotic Syndrome in Children

Guoqun Zhou et al. J Healthc Eng. .

Retraction in

Abstract

Objective: To study the effect of prednisone combined with vitamin D in the treatment of primary nephrotic syndrome in children.

Method: 73 cases of primary nephrotic syndrome admitted to the nephrology department of our hospital were randomly selected and retrospectively analyzed. 36 cases were treated with prednisone as the control group, and 37 cases were treated with prednisone combined with vitamin D as the observation group. The efficacy was compared after 3 months of continuous treatment.

Result: After 3 months of treatment, the blood calcium of the observation group was higher than that of the control group, PTH was lower than that of the control group, and 25-(OH)2D3 and 1,25-(OH)2D3 were higher than those of the control group (P < 0.05). After 1, 2, and 3 months of treatment in the observation group, Scr and 24-h urine protein quantification were lower than those in the control group and eGFR was higher than that in the control group (P < 0.05). CD4+ and CD4+/CD8+ were lower in the observation group than in the control group after 3 months of treatment (P < 0.05). The serum sTfR and TGF-β1 levels were lower in the observation group than in the control group after 3 months of treatment (P < 0.05). The total effective rate of the observation group was 83.78% after 3 months of combined treatment with prednisone and vitamin D, which was significantly higher than the total effective rate of the control group of 61.11% (P < 0.05). The incidence of nausea and vomiting, heartburn, headache, dry cough, hypercalcemia, and constipation during treatment in the observation group was not statistically different from that in the control group (P > 0.05).

Conclusion: Combined treatment of primary nephrotic syndrome in children with prednisone and vitamin D can more significantly improve the level of clinical indicators, improve renal function and immune function, and obtain more satisfactory efficacy, without significantly affecting the safety of treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Compared with the control group before treatment, the differences in serum calcium (a), phosphorus (b), PTH (c), 25-(OH)2D3 (d), and 1,25-(OH)2D3 (e) levels in the observation group were not statistically significant (P > 0.05); compared with the control group after 3 months of treatment, PTH in the observation group was lower than that in the control group, blood calcium, 25-(OH)2D3, and 1,25-(OH)2D3 were higher than those in the control group (P < 0.05), and the difference in blood phosphorus was not statistically significant (P > 0.05); compared with the groups before treatment, after 3 months of therapy, there was no significant change in blood phosphorus in the observation group (P > 0.05), PTH was lower than before treatment and blood calcium, 25-(OH)2D3, and 1,25-(OH)2D3 were higher than those before treatment (P < 0.05). However, the results for the control group were as follows: there was no statistical difference in blood phosphorus, blood calcium, and PTH after 3 months of treatment (P > 0.05), and 25-(OH)2D3 and 1,25-(OH)2D3 were higher than before treatment (P > 0.05).
Figure 2
Figure 2
Compared with the levels of Scr (a), 24-h UTP (b), and eGFR (c) before treatment in the control group, there was no significant difference in the observation group (P > 0.05). Compared with the control group after 1, 2, and 3 months of treatment, the levels of Scr (a) and 24-h UTP (b) were lower and the levels of eGFR (c) were higher in the observation group (P < 0.05).
Figure 3
Figure 3
Compared with the control group before treatment, CD4+ (a), CD8+ (b), and CD4+/CD8+ (c) levels, there was no significant difference in the observation group (P > 0.05); compared with the control group after 3 months of treatment, the observation group CD4+ and CD4+/CD8+ levels were lower (P < 0.05) and CD8+ difference was not significant (P > 0.05). Compared with the group before treatment, CD4+ (a) and CD4+/CD8+ (c) were lower after 3 months of treatment (P < 0.05) and the difference in CD8+ (b) was insignificant (P > 0.05).
Figure 4
Figure 4
Compared with the sTfR (a) and TGF-β1 (b) levels before treatment in the control group, there was no significant difference in the observation group (P > 0.05), and compared with the sTfR and TGF-β1 levels after 3 months of treatment in the control group, both were lower in the observation group (P < 0.05).
See this image and copyright information in PMC

References

    1. Wang C.-S., Greenbaum L. A. Nephrotic syndrome. Pediatric Clinics of North America . 2019;66(1):73–85. doi: 10.1016/j.pcl.2018.08.006. - DOI - PubMed
    1. Tapia C., Bashir K. StatPearls [Internet] Treasure Island, FL, USA: StatPearls Publishing; 2020. Nephrotic Syndrome. - PubMed
    1. Zhang Y, Wang Y. Y., Fu R, Yan X. Evaluation of glucocorticoid treatment on different pathological types of primary nephrotic syndrome. Journal of biological regulators and homeostatic agents . 2019;33(2):427–432. - PubMed
    1. Webb N. J. A., Woolley R. L., Lambe T., et al. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. BMJ . 2019;365 doi: 10.1136/bmj.l1800.l1800 - DOI - PMC - PubMed
    1. Aurelle M., Basmaison O., Ranchin B., et al. Intermittent cholecalciferol supplementation in children and teenagers followed in pediatric nephrology: data from a prospective single-center single-arm open trial. European Journal of Pediatrics . 2020;179(4):661–669. doi: 10.1007/s00431-019-03553-y. - DOI - PubMed

Publication types